Keith Al-Hasani

Keith Al-Hasani

Auto-generated profile, based on publicly available information

Keith Al-Hasani

Epigenetics in Human Health and Disease Laboratory and

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
IKIshant Khurana
Ishant Khurana
HKHarikrishnan Kaipananickal
Harikrishnan Kaipananickal
SMScott Maxwell
Scott Maxwell
SBSørine Birkelund
Sørine Birkelund
ASAnna Syreeni
Anna Syreeni
AEAssam El-Osta
Assam El-Osta
Diabetic nephropathy (DN) is a polygenic disorder with few risk variants showing robust replication in large-scale genome-wide association studies. To understand the role of DNA methylation, it is important to have the prevailing genomic view to distinguish key sequence elements that influence gene expression. This is particularly challenging for DN because genome wide methylation patterns are poorly defined. While methylation is known to alter gene expression the importance of this causal relationship is obscured by array-based technologies since coverage outside promoter regions is low. To overcome these challenges, we performed methylation sequencing using leukocytes derived from participants of the Finnish Diabetic Nephropathy (FinnDiane) type 1 diabetes (T1D) study (n=39) that was subsequently replicated in a larger validation cohort (n=296). Gene body related regions made up >60% of the methylation differences and emphasised the importance of methylation sequencing. We observe differentially methylated genes associated with DN (DDN) in three independent T1D registries originating from Denmark (n=445), Hong Kong (n=107) and Thailand (n=130). Reduced DNA methylation at CTCF and Pol2B sites were tightly connected with DN pathways that include insulin signalling, lipid metabolism and fibrosis. To define the pathophysiological significance of these population findings, methylation indices were assessed in human renal cells such as podocytes and proximal convoluted tubules. The expression of core genes was associated with reduced methylation, elevated CTCF and Pol2B binding and the activation of insulin signalling phosphoproteins in hyperglycaemic cells. These experimental observations also closely parallel methylation-mediated regulation in human macrophage and vascular endothelial cells.

8 June 2022 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
SMSafiya Naina Marikar
Safiya Naina Marikar
AEAssam El-Osta
Assam El-Osta
AJAngus Johnston
Angus Johnston
GSGeorgina Such
Georgina Such
KAKeith Al-Hasani
Keith Al-Hasani
Mapping a new therapeutic route can be fraught with challenges, but recent developments in the preparation and properties of small particles combined with significant improvements to tried and tested techniques offer refined cell targeting with tremendous translational potential. Regenerating new cells through the use of compounds that regulate epigenetic pathways represents an attractive approach that is gaining increased attention for the treatment of several diseases including Type 1 Diabetes and cardiomyopathy. However, cells that have been regenerated using epigenetic agents will still encounter immunological barriers as well as limitations associated with their longevity and potency during transplantation. Strategies aimed at protecting these epigenetically regenerated cells from the host immune response include microencapsulation. Microencapsulation can provide new solutions for the treatment of many diseases. In particular, it offers an advantageous method of administering therapeutic materials and molecules that cannot be substituted by pharmacological substances. Promising clinical findings have shown the potential beneficial use of microencapsulation for islet transplantation as well as for cardiac, hepatic, and neuronal repair. For the treatment of diseases such as type I diabetes that requires insulin release regulated by the patient's metabolic needs, microencapsulation may be the most effective therapeutic strategy. However, new materials need to be developed, so that transplanted encapsulated cells are able to survive for longer periods in the host. In this article, we discuss microencapsulation strategies and chart recent progress in nanomedicine that offers new potential for this area in the future.

20 November 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
BMBelinda J. Morahan
Belinda J. Morahan
CAClarissa Abrie
Clarissa Abrie
KAKeith Al-Hasani
Keith Al-Hasani
MBMitchell B. Batty
Mitchell B. Batty
VCVictoria Corey
Victoria Corey
JGJose F. Garcia-Bustos
Jose F. Garcia-Bustos
Mitosis has been validated by numerous anti-cancer drugs as being a druggable process, and selective inhibition of parasite proliferation provides an obvious opportunity for therapeutic intervention against malaria. Mitosis is controlled through the interplay between several protein kinases and phosphatases. We show here that inhibitors of human mitotic kinases belonging to the Aurora family inhibit P. falciparum proliferation in vitro with various potencies, and that a genetic selection for mutant parasites resistant to one of the drugs, Hesperadin, identifies a resistance mechanism mediated by a member of a different kinase family, PfNek1 (PF3D7_1228300). Intriguingly, loss of PfNek1 catalytic activity provides protection against drug action. This points to an undescribed functional interaction between Ark and Nek kinases and shows that existing inhibitors can be used to validate additional essential and druggable kinase functions in the parasite.

1 March 2019 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
KAKeith Al-Hasani
Keith Al-Hasani
PMPrabhu Mathiyalagan
Prabhu Mathiyalagan
AEAssam El-Osta
Assam El-Osta

20 March 2021 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
SLSebastian Lunke
Sebastian Lunke
SMScott Maxwell
Scott Maxwell
IKIshant Khurana
Ishant Khurana
HKHarikrishnan K.N.
Harikrishnan K.N.
JOJun Okabe
Jun Okabe
AEAssam El-Osta
Assam El-Osta
Background: Valproic acid (VPA) is one of the most commonly used anti-epileptic drugs with pharmacological actions on GABA and blocking voltage-gated ion channels. VPA also inhibits histone deacetylase (HDAC) activity. Suberoylanilide hydroxamic acid is also a member of a larger class of compounds that inhibit HDACs. At the time of this article, there are 123 active international clinical trials for VPA (also known as valproate, convulex, divalproex, and depakote) and SAHA (vorinostat, zolinza). While it is well known that VPA and SAHA influence the accumulation of acetylated lysine residues on histones, their true epigenetic complexity remains poorly understood. Results: Primary human cells were exposed to VPA and SAHA to understand the extent of histone acetylation (H3K9/14ac) using chromatin immunoprecipitation followed by sequencing (ChIP-seq). Because histone acetylation is often associated with modification of lysine methylation, we also examined H3K4me3 and H3K9me3. To assess the influence of the HDAC inhibitors on gene expression, we used RNA sequencing (RNA-seq). ChIP-seq reveals a distribution of histone modifications that is robust and more broadly regulated than previously anticipated by VPA and SAHA. Histone acetylation is a characteristic of the pharmacological inhibitors that influenced gene expression. Surprisingly, we observed histone deacetylation by VPA stimulation is a predominant signature following SAHA exposure and thus defines an acetylation/deacetylation (Ac/Dc) axis. ChIP-seq reveals regionalisation of histone acetylation by VPA and broader deacetylation by SAHA. Independent experiments confirm H3K9/14 deacetylation of NFκB target genes by SAHA. Conclusions: The results provide an important framework for understanding the Ac/Dc axis by highlighting a broader complexity of histone modifications by the most established and efficacious anti-epileptic medication in this class, VPA and comparison with the broad spectrum HDAC inhibitor, SAHA.

20 April 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
IKIshant Khurana
Ishant Khurana
SMScott Maxwell
Scott Maxwell
SRSimon Royce
Simon Royce
PMPrabhu Mathiyalagan
Prabhu Mathiyalagan
TKTom C. Karagiannis
Tom C. Karagiannis
AEAssam El-Osta
Assam El-Osta